[Diabetes mellitus].
The thiazolidinedione compound is known as an insulin-sensitizing agent and is considered a very promising drug, because insulin resistance is a major component of type 2 diabetes. Many reports have demonstrated that the thiazolidinedione has the good hypoglycemic effect in monotherapy and in combination therapy with sulfonylureas, metformin, alpha-glucosidase inhibitors, or insulin. Furthermore, the thiazolidinedione has additional beneficial effects on serum lipids, arterial blood pressure, coagulation-fibrinolysis system, arterial wall cell function. These favorable effects suggest the thiazolidinedione may have inhibitory actions on both macroangiopathy and microangiopathy in patients with diabetes mellitus. However, some patients treated with troglitazone, the first available thiazolidinedione, have suffered from liver dysfunction; in some cases, patients have progressed to hepatic failure and death unfortunately. As the thiazolidinediones are clearly excellent drugs to diabetics with insulin resistance, we should check hepatic function and monitor symptomes of hepatic damage.
Kawano
M
M
Integrated Medicine Omiya Medical Center, Jichi Medical School.
Kanazawa
Y
Y
D001777:Blood Coagulation; D056486:Chemical and Drug Induced Liver Injury; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000503:physiopathology; D004359:Drug Therapy, Combination; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects / Q000627:therapeutic use; D045162:Thiazolidinediones
D007004:Hypoglycemic Agents; D008055:Lipids; D013453:Sulfonylurea Compounds; D013844:Thiazoles; D045162:Thiazolidinediones; C089946:2,4-thiazolidinedione